[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"childhood-lymphoblastic-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:childhood-lymphoblastic-lymphoma":57},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,37],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":4,"maxAge":15,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100609982",false,"NCT07221656","Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration","Inclusion Criteria:\n\n* Acute lymphoblastic leukemia\u002Flymphoma being treated by the pediatric hematology team\n* Receiving calaspargase as part of treatment for malignancy\n\nExclusion Criteria:\n\n* Age \\> 21 years\n* Patients who are actively enrolled on Children's Oncology Group (COG) trial AALL1732 in an inotuzumab containing arm\n* Pregnancy","ALL","21 Years",{"count":17,"type":18},20,"ESTIMATED","OBSERVATIONAL","This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic leukemia or lymphoma.",[22,23],"Childhood Acute Lymphoblastic Leukemia","Childhood Lymphoblastic Lymphoma","NOT_YET_RECRUITING","2026-03-31",{"date":27,"type":28},"2026-04-02","ACTUAL",{"date":30,"type":18},"2027-02-01",{"date":32,"type":18},"2028-12-31",{"name":34,"class":35},"Mayo Clinic","OTHER",1,{"id":38,"slug":4,"hasResults":10,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":4,"eligibilityCriteria":41,"healthyVolunteers":10,"sex":14,"minAge":42,"maxAge":43,"enrollmentInfo":44,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":46,"conditions":47,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":36},"100598404","NCT07071051","Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study","Inclusion Criteria:\n\n* Age 2-21.5 years\n* Confirmed diagnosis of acute lymphoblastic leukemia\u002Flymphoma\n* Planned treatment with Cal-PEG\n* Informed consent obtained from parents or guardians\n\nExclusion Criteria:\n\n* Pre-existing coagulation disorders\n* Known hypersensitivity to asparaginase products\n* Liver failure\n* Any acute or chronic disease that is known to affect coagulation testing (e.g. nephrotic syndrome)\n* Currently pregnant\n* Use of systemic blood thinner within 48 hours prior to study blood draw","2 Years","22 Years",{"count":45,"type":18},15,"This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia\u002Flymphoma (ALL).",[22,23],"RECRUITING","2026-02-11",{"date":51,"type":28},"2026-02-13",{"date":53,"type":28},"2025-07-31",{"date":55,"type":18},"2026-12-31",{"name":34,"class":35},""]